Making gynecological and psychiatric sense out of premenstrual pains, tension and dysphoria

Saudi Medical Journal

Volumn 25, Issue 6, 2004, Pages 717-727

  Qureshi, Naseem A ^a   Al Habeeb, Tariq A ^b  

^a Buraidah Mentalw Health Hospital ^*  (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; BETA ENDORPHIN; BROMOCRIPTINE; BUSERELIN; CITALOPRAM; DANAZOL; DOPAMINE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; ESTROGEN; FLUOXETINE; GESTAGEN; GONADORELIN AGONIST; INSULIN; LEUPRORELIN; NEFAZODONE; NORADRENALIN; PLACEBO; PROGESTERONE; PROLACTIN; PROSTAGLANDIN E1; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SEX HORMONE; TIBOLONE; UNINDEXED DRUG;

ADULT; ALCOHOL CONSUMPTION; BEHAVIOR THERAPY; CIGARETTE SMOKING; COGNITIVE THERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DYSLIPIDEMIA; DYSMENORRHEA; DYSPHORIA; EMOTIONAL STRESS; EXERCISE; FEMALE; FOOD INTAKE; GABAERGIC SYSTEM; GENETIC POLYMORPHISM; HUMAN; HYPERINSULINEMIA; HYPERPROLACTINEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYSTERECTOMY; LIFESTYLE; LUTEAL PHASE; MEDICAL LITERATURE; MEDLINE; MENOPAUSAL SYNDROME; MENSTRUAL CYCLE; NUTRITIONAL DEFICIENCY; OSTEOPOROSIS; OVARIECTOMY; OVULATION; PATHOGENESIS; PATHOPHYSIOLOGY; PEER REVIEW; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PROMOTER REGION; PSYCHOLOGIC ASSESSMENT; QUALITATIVE ANALYSIS; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SEROTONINERGIC SYSTEM; VIRILIZATION;

FEMALE; HUMANS; MOOD DISORDERS; PAIN; PREMENSTRUAL SYNDROME; RISK FACTORS;

EID: 3042813437     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Frank RT. The hormonal causes of pre-menstrual tension. Archives of Neurological Psychiatry 1931; 26: 1053-1057.
2. Greene R, Dalton K. The pre-menstrual syndrome. BMJ 1953; 1: 1007-1014.
3. Connolly M. Premenstrual syndrome: an update on definitions, diagnosis, and management. Advances Psychiatr Treat 2001; 7: 469-477
4. Steiner M. Premenstrual syndromes. Annu Rev Med 1997; 48: 447-455.
5. Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003; 28 Suppl 3: 1-23.
6. Mitwally MF, Kahn LS, Halbreich U. Pharmacotherapy of premenstrual syndromes and premenstrual dysphoric disorder: current practices. Expert Opin Pharmacother 2002; 3 : 1577-1579.
7. Dickerson LM, Mazyck PJ, Hunter MH. Premenstrual syndrome. Am Fam Physician 2003; 67: 1743-1752.
8. Chang AM, Holroyd E, Chau JP. Premenstrual syndrome in employed Chinese women in Hong Kong. Health Care Women Int 1995; 16: 551-561.
9. van den Akker OB, Eves FF, Service S, Lennon B. Menstrual cycle symptom reporting in three British ethnic groups. Soc Sci Med 1995; 40: 1417-1423.
10. Backstrom T, Andreen L, Birzniece V, Bjorn I, Johansson IM, Nordenstam-Haghjo M et al. The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs 2003; 17: 325-342.
11. Bloch M, Schmidt PJ, Rubinow DR. Premenstrual syndrome: evidence for symptom stability across cycles. Am J Psychiatry 1997; 154: 1741-1746.
12. Maskall DD, Lam RW, Misri S, Carter D, Kuan AJ, Yatham LN et al. Seasonality of symptoms in women with late luteal phase dysphoric disorder. Am J Psychiatry 1997; 154: 1436-1441.
13. Seippel L, Bäckström T. Luteal-Phase estradiol relates to symptom severity in patients with premenstrual syndrome. J Clin Endocrinol Metab 1998; 83: 1988-1992.
14. Choi SH, Kang SB, Joe SH. Changes in premenstrual symptoms in women with schizophrenia: a prospective study. Psychosom Med 2001; 63: 822-829.
15. Critchlow DG, Bond AJ, Wingrove J. Mood disorders history and personality assessment in premenstrual dysphoric disorder. J Clin Psychiatry 2001; 62: 688-693.
16. Soares CN, Cohen LS, Otto MW, Haslow BL. Characteristics of women with premenstrual dysphoric disorder (PMDD) who did or did not report history of depression: a preliminary report from Harvard study of Moods and Cycles. J Womens Health Gend Based Med 2001; 10: 873-878.
17. Marvan ML, Diaz-Erosa M, Montesinos A. Premenstrual symptoms in Mexican women with different educational levels. J Psychol 1998; 132: 517-526.
18. Anson O. Exploring the bio-psycho-social approach to premenstrual experiences. Soc Sci Med 1999; 49: 67-80.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington (DC): American Psychiatric Association; 1994.
20. World Health Organization. International Classification of Diseases. 10th version. Geneva: WHO; 1992.
21. Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 2003; 28 Suppl 3: 39-53.
22. Freeman EW. Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis. Psychoneuroendocrinology 2003; 28 Suppl 3: 25-37.
23. Steiner M, Wilkins A. Diagnosis and assessment of premenstrual dysphoria. Psychiatric Ann 1996; 26: 571-575.
24. Smith MJ, Schmidt PJ, Rubinow DR. Operationalizing DSM-IV criteria for PMDD: selecting symptomatic and asymptomatic cycles for research. J Psychiatr Res 2003; 37: 75-83.
25. Praschak-Reider N, Willeit M, Neumeister A, Hilger E, Stastny J, Thierry N, et al. Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder. J Affect Disord 2001; 63: 239-242.
26. Alpay FB, Turban NO. Intermittent versus continuous sertraline therapy in the treatment of premenstrual dysphoric disorder. Int J Fertil Womens Med 2001; 46: 228-231.
27. Hsiao MC, Liu CY, Chen KC, Hsieh TT. Characteristics of women seeking treatment for premenstrual syndrome in Taiwan. Acta Psychiatr Scand 2002; 106: 150-155.
28. Chau JP, Chang AM, Chang AM. Relationship between premenstrual tension syndrome and anxiety in Chinese adolescents. J Adolesc Health 1998; 22: 247-249.
29. Kent JM, Papp LA, Martinez JM, Browne ST, Coplan JD, Klein DF, et al. Specificity of panic responses to CO2 inhalation in panic disorder: a comparison with major depression and premenstrual dysphoric disorder. Am J Psychiatry 2001; 158: 58-67.
30. Basoglu C, Cetin M, Semiz UB, Agargun MY, Ebrine S. Premenstrual exacerbation and suicidal behavior in patients with panic disorder. Compr Psychiatry 2000; 41: 103-105.
31. Blumer D, Hrezog AG, Himmelhoch J, Salgueiro CA, Ling FW. To what extent do premenstrual and interictal dysphoric disorder overlap? J Affect Disord 1998; 48: 215-225.
32. Macdougall M. Review: poor quality studies suggest that vitamin B-6 is beneficial in premenstrual syndrome. Evid Based Nurs 2000; 3: 18-18.
33. Thys-Jacobs S. Micronutrients and the premenstrual syndrome: the case for calcium. J Am Coll Nutr 2000; 19: 220-227.
34. Kendler KS, Karkowski LM, Corev LA, Neale MC. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry 1998; 155: 1234-1240.
35. Facchinetti F, Genazzani AD, Martignoni E, Fioroni L, Nappi G, Genazzani AR. Neuroendocrine changes in luteal function in patients with premenstrual syndrome. J Clin Endocrinol Metab 1993; 76: 1123-1127.
36. Roca CA, Schmidt PJ, Altemus M, Deuster P, Danaceau MA, Putnam K, et al. Differential menstrual cycle regulation of hypothalamic-pituitary-adrenal axis in women with premenstrual syndrome and controls. J Clin Endocrinol Metab 2003; 88: 3057-3063.
37. Girdler SS, Straneva PA, Light KC, Pedersen CA, Morrow AL. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry 2001; 49: 788-797.
38. Sundstrom Poromaa I, Smith S, Gulinello M. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Women Ment Health 2003; 6: 23-41.
39. Praschak-Rieder N, Willeit M, Winkler D, Neumeister A, Hilger E, Zill P, et al. Role of family history and 5HTTLPR polymorphism in female seasonal affective disorder patients with and without premenstrual dysphoric disorder. Eur Neuropsychopharmacol 2002; 12: 129-134.
40. Le Melledo JM, Van Driel M, Coupland NJ, Lott P, Jhangri GS. Response to flumazenil in women with premenstrual dysphoric disorder. Am J Psychiatry 2000; 157: 821-823.
41. Epperson CN, Haga K, Mason GF, Sellers E, Gueorguieva R, Zhang W, et al. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 2002; 59: 851-858.
42. Parry BL, Javeed S, Laughlin GA, Hauger R, Clopton P. Cortisol circadian rhythms during the menstrual cycle and with sleep deprivation in premenstrual dysphoric disorder and normal control subjects. Biol Psychiatry 2000; 48: 920-931.
43. Straneva PA, Maixner W, Light KC, Pedersen CA, Costello NL, Girdler SS. Menstrual cycle, beta-endorphins, and pain sensitivity in premenstrual dysphoric disorder. Health Psychol 2002; 21: 358-367.
44. Le Melledo JM, Merani S, Koszycki D, Bellavance F, Palmour R, Gutkowska J, et al. Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD) during their follicular and luteal phases. Neuropsychopharmacology 1999; 20: 81-91.
45. Griffin LD, Mellon SH. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA 1999; 96: 13512-13517.
46. Bixo M, Allard P, Backstrom T, Mjorndal T, Nyberg S, Spigset O, et al. Binding of (3H) paroxetine to serotonin uptake sites and of (3H) lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment. Psychoneuroendocrinology 2001; 26: 551-564.
47. Melke J, Westberg L, Landen M, Sundblad C, Ericksson O, baghei P et al. Serotonin transporter gene polymorphisms and platelet (3H) paroxetine binding in premenstrual dysphoria. Psychoneuroendocrinology 2003; 28: 446-458.
48. Su TP, Schmidt PJ, Danaceau M, Murphy DL, Rubinow DR. Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-Chlorophenylpiperazine in women with premenstrual syndrome and controls. J Clin Endocrinol Metab 1997; 82: 1220-1228.
49. Korzekwa MI, Lamont JA, Steiner M. Late luteal phase dysphoric disorder and the thyroid axis revisited. J Clin Endocrinol Metab 1996; 81: 2280-2284.
50. Gurguis GN, Yonkers KA, Blakeley JE, Phan SP, Williams A, Rush AJ. Adrenergic receptors in premenstrual dysphoric disorder. II. Neutrophil beta2-adrenergic receptors: Gs protein coupling, phase of menstrual cycle and prediction of luteal phase symptom severity. Psychiatry Res 1998; 79: 31-42.
51. Monagle L, Krogh DV, Jossa F, Farinaro E, Trevisan M. Perimenstrual symptom prevalence rates: an Italian-American comparison. Am J Epidemiol 1993; 138: 1070-1081.
52. Critchlow DG, Bond AJ, Wingrove J. Women with premenstrual dysphoric disorder do not recall aberrant parenting. J Psychosom Obstet Gynaecol 2002; 23: 143-146.
53. Girdler SS, Pedersen CA, Straneva PA, Leserman J, Stanwyck CL, Benjamin S, et al. Dysregulation of cardiovascular and neuroendocrine responses to stress in premenstrual dysphoric disorder. Psychiatry Res 1998; 81: 163-178.
54. Budeiri DJ, Li Wan Po A, Dornan JC. Clinical trials of treatments of premenstrual Syndromes: entry criteria and scales of measuring treatment outcomes. Br J Obstet Gynecol 1994; 101: 689-695.
55. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Women Ment Health 2003; 6: 203-209.
56. National Institute of Mental Health. NIMH premenstrual syndrome workshop guidelines. Rockville (MD): National Institute of Mental Health; 1983. p.14-15.
57. Goodnick PJ, Chaudry T, Artadi J, Arcey S. Women's issues in mood disorders. Expert Opin Pharmacother 2000; 1: 903-916.
58. Freeman EW. Current update of hormonal and psychotropic drug treatment of premenstrual dysphoric disorder. Curr Psychiatry Rep 2002; 4: 435-440.
59. Wyatt K, Dimmock P, Jones P, Obhrai M, O'Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systemic review. BMJ 2001; 323: 776.
60. Yonkers K. Review: progesterone or progestogens lead to a marginal reduction in premenstrual syndrome symptoms. Evid Based Ment Health 2002; 5: 56.
61. Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001; 10: 561-569.
62. Mansour D. Experience with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being. Eur J Contracept Reprod Health Care 2002; 7 Suppl 3: 35-41.
63. Taskin O, Gokdeniz R, Yalcinoglu A, Buhur A, Burak F, Atmaca R, et al. Placebo-controlled cross-over study of effects of tibolone on premenstrual symptoms and peripheral beta-endorphin concentrations in premenstrual syndrome. Hum Reprod 1998; 13: 2402-2405.
64. Wyatt KM, Dimmock PW, O'Brien PM. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2002; 4: CD001396.
65. Miner C, Brown E, McCray S, Gonzales J, Wohlreich M. Weekly luteal phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002; 24: 417-433.
66. Pearlstein T, Joliat MJ, Brown EB, Miner CM. Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment. Am J Obstet Gynecol 2003; 188: 887-895
67. Pearlstein T. Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard? Drugs 2002; 62: 1869-1885.
68. Freeman EW, Jabara S, Sondheimer SJ, Auletto R. Citalopram in PMS patients with prior SSRIs treatment failure: a preliminary study. J Womens Health Gend Based Med 2002; 11: 459-464.
69. Hsiao MC, Liu CY. Effective open-label treatment of premenstrual dysphoric disorder with venlafaxine. Psychiatry Clin Neurosci 2003; 57: 317-321.
70. Endicott J, Amsterdam J, Eriksson E, Frank E, Freeman E, Hirschfeld R, et al. Is premenstrual dysphoric disorder a distinct clinical entity? J Womens Health Gend Based Med 1999; 8: 663-679
71. Macdougall M, Steiner M. Treatment of premenstrual dysphoria with selective serotonin re-uptake inhibitors: focus on safety. Expert Opin Drug Saf 2003; 2: 161-166.
72. Schellenberg GR. Treatment of the premenstrual syndrome with agnus castus fruit extract: prospective, randomized, placebo controlled study. BMJ 2001; 322: 134-138.
73. Tamborini A, Taurelle R. Value of standardized Ginkgo biloba extract (EGb 761) in the management of congestive symptoms of premenstrual syndrome. Rev Fr Gynecol Obstet 1993; 88: 447-457.
74. Girman A, Lee R, Kligler B. An integrative medicine approach to premenstrual syndrome. Am J Obstet Gynecol 2003; 188 (5 Suppl): S56-S65.
75. Casper RF, Hearn MT. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am J Obstet Gynecol 1990; 162: 105-109
76. Freeman EW, Rickels K. Characteristics of placebo responses in medical treatment of premenstrual syndrome. Am J Psychiatry 1999; 156: 1403-1408.
77. Severino SK, Yonkers KA. A literature review of psychotic symptoms associated with the premenstruum. Psychosomatics 1993; 34: 299-306.
78. Hartlage SA, Gehlert S. Differentiating premenstrual dysphoric disorder from premenstrual exacerbations of other disorders: a methods dilemma. Clin Psychol 2001; 8: 242-253.
79. Chawla A, Swindle R, Long S, Kennedy S, Sternfeld B. Premenstrual dysphoric disorder: is there an economic burden of illness? Med Care 2002; 40: 1101-1112.
80. Wyatt KM, Dimmock PW, Frischer M, Jones PW, O' Brien SP. Prescribing patterns in PMS. BMC Womens Health 2002; 2: 4.
81. Landen M, Eriksson E. How does premenstrual dysphoric disorder relate to depression and anxiety disorders?. Depress Anxiety 2003; 17: 122-129.
82. Roca CA, Schmidt PJ, Smith MJ, Danaceau MA, Murphy DL, Rubinow DR. Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. Am J Psychiatry 2002; 159: 1876-1881.
83. Miller MN, Miller BE, Chinouth R, Coyle BR, Brown GR. Increased premenstrual dosing of nefazodone relieves premenstrual magnification of depression. Depress Anxiety 2002; 15: 48-51.
84. Hunter MS, Ussher JM, Browne SJ, Cariss M, Jelley R, Katz M. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002; 23: 193-199.